Abirami Veluchamy

Dr. Abirami Veluchamy


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSonia Shah
Sonia Shah
AHAlbert Henry
Albert Henry
CRCarolina Roselli
Carolina Roselli
HLHonghuang Lin
Honghuang Lin
GSGarðar Sveinbjörnsson
Garðar Sveinbjörnsson
RLR. Thomas Lumbers
R. Thomas Lumbers
Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained. We report results from a GWAS meta-analysis of HF comprising 47,309 cases and 930,014 controls. Twelve independent variants at 11 genomic loci are associated with HF, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, suggesting shared genetic aetiology. Functional analysis of non-CAD-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homoeostasis (BAG3), and cellular senescence (CDKN1A). Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.

7 December 2016 in Pain
Verified
Journal Article
Open access
HHHarry L. Hébert
Harry L. Hébert
Abirami VeluchamyAbirami Veluchamy
Abirami Veluchamy
NTNicola Torrance
Nicola Torrance
BSBlair Smith
Blair Smith

7 September 2017 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
HHHarry L Hébert
Harry L Hébert
BSBridget Shepherd
Bridget Shepherd
KMKeith Milburn
Keith Milburn
Abirami VeluchamyAbirami Veluchamy
Abirami Veluchamy
WMWeihua Meng
Weihua Meng
CPColin N A Palmer
Colin N A Palmer
The prevalence of diabetes worldwide has been steadily increasing over the past 20 years. In 1997 it was estimated to be 124 million, 1 in 2015 it was estimated to be 415 million among 20–70 year olds, and this is expected to rise to 642 million by 2040. 2 In the UK, an estimated 4 million people have diabetes either diagnosed or undiagnosed. 2 This represents a significant burden on health care resources, 3 particularly given that type 2 diabetes (T2D) is associated with comorbidities including obesity, 4 cardiovascular disease, 5 chronic kidney disease 6 and neuropathy. 7 T2D is a complex disorder, caused by a combination of environmental and genetic factors. 8 Before the first genome-wide association study (GWAS) was conducted for T2D in 2007, 9 very few genetic loci were known to be involved with T2D. However, linkage and candidate-gene association studies have often failed to replicate findings through lack of power and inadequate knowledge of the underlying biological pathways. 10, 11

1 August 2020 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
NTNicola Torrance
Nicola Torrance
Abirami VeluchamyAbirami Veluchamy
Abirami Veluchamy
YZYiling Zhou
Yiling Zhou
EFEmma H. Fletcher
Emma H. Fletcher
EMEilidh Moir
Eilidh Moir
BSBlair Smith
Blair Smith

18 January 2018 in Pain
Verified
Journal Article
Closed access
Abirami VeluchamyAbirami Veluchamy
Abirami Veluchamy
HHHarry L. Hébert
Harry L. Hébert
WMWeihua Meng
Weihua Meng
CPColin N.A. Palmer
Colin N.A. Palmer
BSBlair Smith
Blair Smith
Neuropathic pain (NP) is an increasingly common chronic pain state and a major health burden, affecting approximately 7% to 10% of the general population. Emerging evidence suggests that genetic factors could partially explain individual susceptibility to NP and the estimated heritability in twins is 37%. The aim of this study was to systematically review and summarize the studies in humans that have investigated the influence of genetic factors associated with NP. We conducted a comprehensive literature search and performed meta-analyses of all the potential genetic variants associated with NP. We reviewed 29 full-text articles and identified 28 genes that were significantly associated with NP, mainly involved in neurotransmission, immune response, and metabolism. Genetic variants in HLA genes, COMT, OPRM1, TNFA, IL6, and GCH1, were found to have an association with NP in more than one study. In the meta-analysis, polymorphisms in HLA-DRB1*13 (odds ratio [OR], 2.96; confidence interval [CI], 1.93-4.56), HLA-DRB1*04 (OR, 1.40; CI, 1.02-1.93), HLA-DQB1*03 (OR, 2.86; CI, 1.57-5.21), HLA-A*33 (OR, 2.32; CI, 1.42-3.80), and HLA-B*44 (OR, 3.17; CI, 2.22-4.55) were associated with significantly increased risk of developing NP, whereas HLA-A*02 (OR, 0.64; CI, 0.47-0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; CI, 0.27-1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with NP. These findings demonstrate an important and specific contribution of genetic factors to the risk of developing NP. However, large-scale replication studies are required to validate these candidate genes. Our review also highlights the need for genome-wide association studies with consistent case definition to elucidate the genetic architecture underpinning NP.

29 August 2017 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MSMoneeza K Siddiqui
Moneeza K Siddiqui
CMCyrielle Maroteau
Cyrielle Maroteau
Abirami VeluchamyAbirami Veluchamy
Abirami Veluchamy
ATAleksi Tornio
Aleksi Tornio
RTRoger Tavendale
Roger Tavendale
PCPREDICTION-ADR Consortium
PREDICTION-ADR Consortium
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms. We examined the association of this variant with statin intolerance ascertained from electronic medical records in the GoDARTS study. In the GoDARTS cohort, the LILRB5 Asp247 variant was associated with statin intolerance (SI) phenotypes; one defined as having raised CK and being non-adherent to therapy [odds ratio (OR) 1.81; 95% confidence interval (CI): 1.34–2.45] and the other as being intolerant to the lowest approved dose of a statin before being switched to two or more other statins (OR 1.36; 95% CI: 1.07–1.73). Those homozygous for Asp247 had increased odds of developing both definitions of intolerance. Importantly the second definition did not rely on CK elevations. These results were replicated in adjudicated cases of statin-induced myopathy in the PREDICTION-ADR consortium (OR1.48; 95% CI: 1.05–2.10) and for the development of myalgia in the JUPITER randomized clinical trial of rosuvastatin (OR1.35, 95% CI: 1.10–1.68). A meta-analysis across the studies showed a consistent association between Asp247Gly and outcomes associated with SI (OR1.34; 95% CI: 1.16–1.54). This study presents a novel immunogenetic factor associated with statin intolerance, an important risk factor for cardiovascular outcomes. The results suggest that true statin-induced myalgia and non-specific myalgia are distinct, with a potential role for the immune system in their development. We identify a genetic group that is more likely to be intolerant to their statins.